Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Aug 24;56(9):426.
doi: 10.3390/medicina56090426.

Transition from Childhood to Adulthood in Patients with Duchenne Muscular Dystrophy

Eliza Wasilewska  1 , Sylwia Małgorzewicz  2 , Agnieszka Sobierajska-Rek  3 , Joanna Jabłońska-Brudło  3 , Lucyna Górska  1 , Karolina Śledzińska  4 , Joanna Bautembach-Minkowska  5 , Jolanta Wierzba  4
Affiliations

Transition from Childhood to Adulthood in Patients with Duchenne Muscular Dystrophy

Eliza Wasilewska et al. Medicina (Kaunas). .

Abstract

Recently, progress has been observed in the knowledge about Duchenne Muscular Dystrophy (DMD), which is a severe and commonly diagnosed genetic myopathy in childhood, historically resulting in early death. Currently, there are a lot of methods available to improve the clinical course of DMD and extend patients' life expectancy to more than 30 years of age. The key issue for DMD patients is the period between 16-18 years of age, which is described as a transition from pediatric- to adult-oriented healthcare. Adolescents and adults with DMD have highly complex healthcare needs associated with long-term steroid usage, orthopedic, ventilation, cardiac, and gastrointestinal problems. The current paper provides a comprehensive overview of special healthcare needs related to the transfer of a patient with DMD from child-oriented to adult-oriented care. Additionally, the need to organize effective care for adults with DMD is presented.

Keywords: duchenne muscular dystrophy; health needs; transition process.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Wakap S.N., Lambert D.M., Olry A., Rodwell C., Gueydan C., Lanneau V., Murphy D., Le Cam Y., Rath A. Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database. Eur. J. Hum. Genet. 2019;28:165–173. doi: 10.1038/s41431-019-0508-0. - DOI - PMC - PubMed
    1. [(accessed on 10 May 2020)]; Available online: https://www.orpha.net/consor/cgi-bin/index.php.
    1. Valdez R., Ouyang L., Bolen J. Public Health and Rare Diseases: Oxymoron No More. Prev. Chronic Dis. 2016;13:E05. doi: 10.5888/pcd13.150491. - DOI - PMC - PubMed
    1. [(accessed on 30 April 2020)]; Available online: https://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf.
    1. Birnkrant D.J., Bushby K., Bann C.M., Apkon S.D., Blackwell A., Brumbaugh D., E Case L., Clemens P.R., Hadjiyannakis S., Pandya S., et al. Diagnosis and management of Duchenne muscular dystrophy, part 1: Diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management. Lancet Neurol. 2018;17:251–267. doi: 10.1016/S1474-4422(18)30024-3. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources